Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.47 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | Q9HBH1 | 2/20 | 0.39 | |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4954258 | 1.00 | GRIK1 (0.47) | GRIK1GRIK2CPA1PDFCYP2C19 | |
| SCHEMBL4955308 | 0.81 | PDF (0.52) | GRIK1GRIK2CPA1PDFABCC4 | |
| SCHEMBL4955312 | 0.81 | PDF (0.52) | GRIK1GRIK2CPA1PDFABCC4 | |
| SCHEMBL11374471 | 0.78 | GRIK1 (0.52) | GRIK1GRIK2CPA1CYP2C19ABCC4 | |
| SCHEMBL891727 | 0.76 | GRIK1 (0.64) | GRIK1GRIK2CPA1CYP2C19ABCC4 | |
| SCHEMBL6135706 | 0.76 | CA2 (0.42) | ||
| SCHEMBL1373680 | 0.74 | FOLH1 (0.52) | — | |
| SCHEMBL6050002 | 0.74 | GRIK1 (0.75) | GRIK1GRIK2CPA1CYP2C19ABCC4 | |
| SCHEMBL4321258 | 0.73 | SLC1A3 (0.46) | CPA1 | |
| SCHEMBL29169438 | 0.73 | GRIK1 (0.47) | GRIK1GRIK2CPA1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323448-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2008-01-29 | — | — | US | disclosed |
| US-7148198-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2006-12-12 | — | — | US | disclosed |
| US-20060276409-A1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2006-12-07 | — | — | US | disclosed |
| US-20050014702-A1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2005-01-20 | — | — | US | disclosed |
| US-6787522-B2 | BACTERIAL POLYPEPTIDE DEFORMYLASE (PDF) INHIBITORS, N-FORMYL HYDROXYLAMINE DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2004-09-07 | — | — | US | disclosed |
| EP-1052984-B1 | ANTIBACTERIAL AGENTS | VERNALIS OXFORD LTD (GB) | 2004-05-12 | — | — | EP | disclosed |
| US-20020165167-A1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2002-11-07 | — | — | US | disclosed |
| US-6423690-B1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2002-07-23 | — | — | US | disclosed |
| EP-1052984-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999039704-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276409-A1 | Antibacterial agents | CBR3, CBR1, SIGMAR1 | GRIK1 4451/4885GRIK2 4759/4885CPA1 2674/4885 |
| US-20050014702-A1 | Antibacterial agents | CBR3, CBR1, SIGMAR1 | GRIK1 4451/4885GRIK2 4759/4885CPA1 2674/4885 |
| US-20020165167-A1 | Antibacterial agents | CBR1, CBR3, SIGMAR1 | GRIK1 4230/4885GRIK2 4673/4885CPA1 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.